Ultragenyx Pharmaceutical (RARE) Net Income towards Common Stockholders (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$185.0 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$185.0 million, down 22.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$608.9 million (down 4900.69% YoY), and the FY2025 annual result was -$575.0 million, down 8114.29% from the prior year.
• Net Income towards Common Stockholders slipped to -$185.0 million in Q1 2026 per RARE's latest filing, from -$128.6 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $428.8 million in Q4 2024 and troughed at -$245.1 million in Q3 2022.
• A 5-year average of -$122.5 million and a median of -$153.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders slumped 235.77% in 2022, then soared 447.06% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$153.5 million in 2022, then gained by 19.5% to -$123.6 million in 2023, then soared by 447.06% to $428.8 million in 2024, then slumped by 129.98% to -$128.6 million in 2025, then tumbled by 43.91% to -$185.0 million in 2026.
• Business Quant data shows RARE's Net Income towards Common Stockholders at -$185.0 million in Q1 2026, -$128.6 million in Q4 2025, and -$180.4 million in Q3 2025.